NCT01693614 - Safety and Efficacy of BKM120 in Relapsed and Refractory NHL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

July 21, 2017

Study Completion Date

July 21, 2017

Conditions

Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

Interventions

DRUG

Buparlisib

100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days

Trial Locations (20)

5530

Novartis Investigative Site, Yvoir

8000

Novartis Investigative Site, Bruges

10017

Memorial Sloan Kettering Dept of Onc., New York

10408

Novartis Investigative Site, Gyeonggi-do

13273

Novartis Investigative Site, Marseille

20133

Novartis Investigative Site, Milan

20141

Novartis Investigative Site, Milan

29425

Medical University of South Carolina -Hollings Cancer Center Medical Univ of South Carolina, Charleston

35019

Novartis Investigative Site, Rennes

35040

Novartis Investigative Site, Izmir

37007

Novartis Investigative Site, Salamanca

55139

Novartis Investigative Site, Samsun

60590

Novartis Investigative Site, Frankfurt

68198

University of Nebraska Medical Center Univ Nebraska, Omaha

69495

Novartis Investigative Site, Pierre-Bénite

77030

University of Texas MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3), Houston

97080

Novartis Investigative Site, Würzburg

02114

Massachusetts General Hospital, Boston

06351

Novartis Investigative Site, Seoul

08907

Novartis Investigative Site, L'Hospitalet de Llobregat